Allan D Sniderman Biography

I am Canadian. Our country is vast and beautiful. Our citizens come from everywhere and by and large we live well with each other. My opportunity to contribute is the result of an educational system that was open to the less privileged and a society that is concerned with the welfare of its citizens.

With the help of many colleagues, my major scientific achievements are the demonstration that LDL composition varies, that apoB equals atherogenic particle number, and that apoB and the apoB/apoA-I ratio are superior to the cholesterol indices as markers of the lipoprotein-related risk of vascular disease and the adequacy of LDL-lowering therapy.

Most interesting for me has been the gradual explication of the mechanisms by which adipose tissue and the liver interact to produce increased apoB100 secretion and increased LDL particle number in plasma. Plasma apoB is a function in the first instance of the flux of cholesterol across the hepatocyte and this process is powerfully driven by the total flux of fatty acids across the membrane of the hepatocyte. It is the metabolic intersection between fatty acids, cholesterol, and apoB that accounts for the atherogenic dyslipoproteinemia that is so common in the energy excess states that we call obesity.